Sarepta Therapeutics, Inc. (BVMF:S1RP34)
Brazil · Delayed Price · Currency is BRL 4.700
-0.040 (-0.84%)
At close: Nov 12, 2025
Sarepta Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| 2,414 | 1,902 | 1,243 | 933.01 | 701.89 | 540.1 | Upgrade | |
Revenue Growth (YoY) | 47.15% | 52.97% | 33.26% | 32.93% | 29.95% | 41.82% | Upgrade |
Cost of Revenue | 1,970 | 1,124 | 1,028 | 1,017 | 862.13 | 785.63 | Upgrade |
Gross Profit | 443.83 | 778.36 | 215.61 | -84.07 | -160.24 | -245.53 | Upgrade |
Selling, General & Admin | 527.29 | 557.87 | 481.87 | 451.42 | 282.66 | 317.88 | Upgrade |
Amortization of Goodwill & Intangibles | 2.55 | 2.41 | 1.56 | 0.71 | 0.71 | 0.66 | Upgrade |
Operating Expenses | 529.84 | 560.28 | 483.43 | 452.14 | 283.37 | 318.54 | Upgrade |
Operating Income | -86.01 | 218.08 | -267.82 | -536.2 | -443.61 | -564.06 | Upgrade |
Interest Expense | -21.77 | -18.39 | -22.01 | -53.25 | -63.53 | -59.95 | Upgrade |
Interest & Investment Income | 30.58 | 30.64 | 36.26 | 16.49 | 0.35 | 2.97 | Upgrade |
Other Non Operating Income (Expenses) | -4.29 | -2.85 | 0.62 | -6.92 | -0.94 | 0.52 | Upgrade |
EBT Excluding Unusual Items | -81.5 | 227.48 | -252.96 | -579.88 | -507.72 | -620.52 | Upgrade |
Merger & Restructuring Charges | -40.51 | - | - | - | - | - | Upgrade |
Gain (Loss) on Sale of Investments | -3.39 | 41.13 | 19.39 | 8.66 | -4.33 | 4.49 | Upgrade |
Gain (Loss) on Sale of Assets | - | - | 102 | - | 102 | 108.07 | Upgrade |
Asset Writedown | - | - | - | - | - | -0.1 | Upgrade |
Other Unusual Items | -126.79 | -7.84 | -388.53 | -118.74 | -8.9 | -45 | Upgrade |
Pretax Income | -252.19 | 260.77 | -520.1 | -689.96 | -418.95 | -553.07 | Upgrade |
Income Tax Expense | 19.33 | 25.54 | 15.88 | 13.53 | -0.17 | 1.06 | Upgrade |
Net Income | -271.51 | 235.24 | -535.98 | -703.49 | -418.78 | -554.13 | Upgrade |
Net Income to Common | -271.51 | 235.24 | -535.98 | -703.49 | -418.78 | -554.13 | Upgrade |
Shares Outstanding (Basic) | 98 | 95 | 92 | 88 | 81 | 78 | Upgrade |
Shares Outstanding (Diluted) | 98 | 108 | 92 | 88 | 81 | 78 | Upgrade |
Shares Change (YoY) | -2.62% | 16.75% | 5.53% | 7.75% | 4.24% | 5.90% | Upgrade |
EPS (Basic) | -2.77 | 2.47 | -5.80 | -8.03 | -5.15 | -7.11 | Upgrade |
EPS (Diluted) | -2.77 | 2.34 | -5.80 | -8.03 | -5.15 | -7.11 | Upgrade |
Free Cash Flow | -381.1 | -342.74 | -577.1 | -356.17 | -481.66 | 25.26 | Upgrade |
Free Cash Flow Per Share | -3.89 | -3.18 | -6.25 | -4.07 | -5.93 | 0.32 | Upgrade |
Gross Margin | 18.39% | 40.92% | 17.34% | -9.01% | -22.83% | -45.46% | Upgrade |
Operating Margin | -3.56% | 11.47% | -21.54% | -57.47% | -63.20% | -104.44% | Upgrade |
Profit Margin | -11.25% | 12.37% | -43.11% | -75.40% | -59.66% | -102.60% | Upgrade |
Free Cash Flow Margin | -15.79% | -18.02% | -46.41% | -38.17% | -68.62% | 4.68% | Upgrade |
EBITDA | -36.28 | 255.81 | -223.43 | -494.34 | -405.59 | -537.6 | Upgrade |
EBITDA Margin | -1.50% | 13.45% | -17.97% | -52.98% | -57.79% | -99.54% | Upgrade |
D&A For EBITDA | 49.72 | 37.72 | 44.4 | 41.86 | 38.02 | 26.46 | Upgrade |
EBIT | -86.01 | 218.08 | -267.82 | -536.2 | -443.61 | -564.06 | Upgrade |
EBIT Margin | -3.56% | 11.47% | -21.54% | -57.47% | -63.20% | -104.44% | Upgrade |
Effective Tax Rate | - | 9.79% | - | - | - | - | Upgrade |
Revenue as Reported | 2,414 | 1,902 | 1,243 | 933.01 | 701.89 | 540.1 | Upgrade |
Advertising Expenses | - | 32 | 28.6 | 14.6 | 7.7 | - | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.